Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
Authors:
Open Access
- 4 March 2016
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 30 (8) , 1763-1766
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 studyLeukemia, 2015
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2014
- Diagnostic and Treatment Dilemma of Dual Pathology of Lung Cancer and Disseminated TuberculosisJournal of Clinical Oncology, 2014
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft ModelsMolecular Cancer Therapeutics, 2013
- Heterogeneity of young and aged murine hematopoietic stem cells revealed by quantitative clonal analysis using cellular barcodingBlood, 2013
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignanciesBlood, 2011
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and AlemtuzumabThe Journal of Immunology, 2011
- Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cellsBritish Journal of Haematology, 2010
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialThe Lancet, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010